Last Modified: December 18, 2005
Conference Dates: January 26, 2006
Conference Location: Santa Monica, CA
Sponsoring Group: The Center for Biomedical Continuing Education
Conference Web Page URL: www.thecbce.com/currentactivities.asp
Topics Covered: EGFR Inhibitors, Angiogenesis Inhibitors, Proapoptotic Agents, mTor/Map kinase/Signal Transduction/Akt, Novel Cytotoxics, Vaccines/Gene Therapy, Related Disease States and Radiation Therapy
Conference Objectives: After attending this activity, participants should be able to:
Who Should Attend: The target audience will include medical and radiation oncologists, pathologists, community practitioners, researchers, fellows, and junior faculty involved in the diagnosis and management of patients with thoracic malignancies.
Registration Information: www.thecbce.com/currentactivities.asp
Conference Fees: Physician (in practice or academic research): $195. Fellow (with letter of fellow status from director): complimentary. Industry/All others: $1,895 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)
Continuing Education: Yes
Apr 16, 2014 - Targeting a cancer cell's heat shock response protein 70 with panobinostat to induce autophagy in the stressed cell, and then introducing an autophagy inhibitor to force the cell to die off, may be an effective novel treatment strategy for breast cancer, according to a Nov. 16 press briefing presented at the American Association for Cancer Research -- National Cancer Institute -- European Organisation for Research and Treatment of Cancer International Conference, "Molecular Targets and Cancer Therapeutics," held from Nov. 15 to 19 in Boston.
Apr 16, 2014
Feb 9, 2011